Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

Maximilian Stahl, MD

Medical Oncology

Make an Appointment
Watch Video

Maximilian Stahl, MD


  • Physician
  • Instructor in Medicine, Harvard Medical School


Clinical Interests

  • Acute and chronic leukemia
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia
  • Myelodysplastic syndrome
  • Myeloproliferative neoplasms

Contact Information

  • Appointments617-632-6028 (new patients)
    617-582-7386 x1 (follow-up)
  • Fax617-632-2933


Dr. Stahl graduated from Hannover Medical School in Hannover, Germany. He received his internal medicine residency training at the Yale School of Medicine where he also served as a chief medical resident. He then completed his Hematology and Oncology fellowship training at the Memorial Sloan Kettering Cancer Center in New York City. He is currently a member of the Adult Leukemia Group at Dana-Farber Cancer Institute and also a member of the faculty at Harvard Medical School.   

Board Certification:

  • Internal Medicine


  • Memorial Sloan Kettering Cancer Center


  • Yale-New Haven Hospital

Medical School:

  • Hannover Medical School

Recent Awards:

  • 2017: HONORS Award by the American Society of Hematology
  • 2016, 2017, 2020: American Society of Hematology Abstract achievement award
  • 2016: Yale University School of Medicine Samuel D. Kushlan, MD award (Teaching and Clinical Care)
  • 2017: Yale University School of Medicine Stephen R. Shell, MD award (Teaching and Clinical Care)
  • 2020: Young Investigator Award by the Conquer Cancer Foundation of the American Society of Clinical Oncology
  • 2021: Chief Fellow, Memorial Sloan Kettering Cancer Center


I conduct clinical and translational research in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

In my clinical research, I evaluate outcomes achieved with novel therapeutic approaches for AML, MDS and MPNs with a focus on identifying molecular predictors of these outcomes. For example, I have examined the effectiveness of hypomethylating agents (HMA) in AML (Blood Advances 2018) and MDS (Cancer 2017 and Blood 2018), immunosuppressive therapy in MDS (Blood Advances 2018 and Haematologica 2020), interferon therapy in MPNs (Leukemia 2020 and Clin Lymphoma, Myeloma, Leukemia 2020) and leukapheresis in hyperleukocytosis (Leukemia 2020 and Transfusion 2020). I have also studied molecular predictors of response to the bcl-2 inhibitor venetoclax in AML (Blood Advances 2021).
In addition, I have in interest in translational research with the goal to bring basic scientific discoveries from the laboratory bench to the clinic in order to benefit leukemia patients. Towards this goal, I conduct early phase clinical trials testing novel treatment approaches for patients with AML, MDS and MPNs.
Lastly, I have a strong interest in medical education and consider teaching fellows, residents and medical students an important part of my daily work. I served as chief medical resident during my residency training at Yale and as a chief fellow during my fellowship training at Memorial Sloan Kettering Cancer Center.


Dana-Farber Cancer Institute
450 Brookline Ave
Dana 2037
Boston, MA 02215
Get Directions